Final Program

324 TUESDAY • MAY 17
918 Sarcoidosis Associated Pulmonary Hypertension Across the
World: Results of a Registry of Sarcoidosis Associated
Pulmonary Hypertension (ReSAPH)/J.B. Barney, O.A. Shlobin,
D.A. Culver, M.B. Scholand, E.M. Carmona, V. Kouroanos, E.
Alhamad, F. Cordova, B. Van Den Blink, R.P. Baughman,
Birmingham, AL, p.A6201
919 Scalp Hair Cortisol and Testosterone; Related to Psychological
Distress in Patients with Sarcoidosis?/M.J.G. Van Manen, V.L.
Wester, E.F.C. Van Rossum, L.M. Van Den Toorn, B. Van Den
Blink, K.Y. Dorst, Y.B. De Rijke, H.C. Hoogsteden, M.S.
Wijsenbeek, Rotterdam, Netherlands, p.A6202
920 Diagnostic Yield of Endobronchial Ultrasound-Guided
Transbronchial Needle Aspiration for the Diagnosis of
Sarcoidosis: A Preliminary Comparison of Sensitivity in Black
versus White Patients/E.S. Rains, M. Calder, T. Meyer, V. Ciocca,
L. Lande, Wynnewood, PA, p.A6203
921 Proprosal for a Neurosarcoidosis Classification System/D.
Perlman, A. Johnson, M. Bhargava, M. Fiol, Minneapolis, MN, p.A6204
922 Prevalence and Risk Factor of Proteinuria in Sarcoidosis/A.
Chopra, P. Brasher, R. Zhang, H. Chaudhry, A. Asif, M.A. Judson,
Albany, NY, p.A6205
923 Evolution of EBUS in the Diagnosis of Sarcoidosis in Ireland/K.
Sharma, A. O’Regan, Dublin, Ireland, p.A6206
924 Study on Staging of Sarcoidosis Using the Combination of
Chest Computed Tomography Scan and Radiography/Y. Zhang,
D. Weng, Shanghai, China, p.A6207
925 The Importance of Diagnostic Metabolic Syndrome During the
Course of Sarcoidosis/J.L. Videnovic Ivanov, V.V.
Vucinic-Mihailovic, S. Filipovic-Stepic, D. Gostiljac, M. Stjepanovic,
Belgrade, Serbia, p.A6208
C102
POSTER DISCUSSION SESSION
STATEGIES TO UNDERSTAND ILD: REGISTRIES,
PROGNOSTIC INDICATORS AND MORE
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 304 (South Building, Esplanade Level)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15
Chairing: T. Corte, MD, PhD, Sydney, Australia
R. Bascom, MD, MPH, Hershey, PA
G.P. Cosgrove, MD, Denver, CO
201 Detecting and Treatment Pulmonary Thromboembolism in
Patients with Rapidly Progressive Interstitial Pneumonias
Improve the Prognosis/S. Hamada, H. Ichiyasu, H. Ideguchi, H.
Okabayashi, S. Okamoto, M. Inaba, S. Ushijima, N. Hirata, T.
Yoshinaga, H. Kohrogi, Kumamoto City, Japan, p.A6209
202 Establishment of a National Registry for Pulmonary Alveolar
Proteinosis in the United States/B. Carey, C. Chalk, A. Toth, M.
Nowell-Bostic, K. Uchida, T. Suzuki, B.C. Trapnell, Cincinnati, OH,
p.A6210
203 A Multicentre Evaluation of Inter-Multidisciplinary Team
Agreement for Diagnosis in Diffuse Lung Disease/S.L. Walsh,
A.U. Wells, V. Poletti, A. Dubini, S. Piciucchi, E. Bendstrup, L.B.
Madsen, F. Rasmussen, J.C. Grutters, K. Seldenrijk, M. Van
Oosterhout, H.W. Van Es, D. Valeyre, H. Nunes, P. Yves Brillet, M.
Kambouchner, A. Morais, J. Pereira, C.S. Moura, B. Gooptu, S.
Desai, S. Pomplun, T. Johkoh, J. Fukuoka, H. Taniguchi, J. Jacob,
C. Sayer, K. Flaherty, J.L. Myers, M.A. Kokosi, D. Hansell, London,
United Kingdom, p.A6211
204 Mortality and Comorbidity Among Danish ILD Patients
1998-2010/O. Hilberg, A. Lokke, C. Hyldgaard, E. Bendstrup,
Aarhus, Denmark, p.A6212
205 Quality and Bias of Internet Health Information for Idiopathic
Pulmonary Fibrosis/J.H. Fisher, D. O’Connor, A.M. Flexman, S.
Shapera, C.J. Ryerson, Toronto, Canada, p.A6213
206 Patients with Both Possible UIP Pattern on High-Resolution CT
and Consistent with UIP Pattern on Histopathological Criteria
Could Include Those of Interstitial Lung Diseases with Known
Causes Rather than Idiopathic Pulmonary Fibrosis ~a
Retrospective Anal/S. Hashimoto, M. Ueyama, S. Terada, T.
Nakanishi, N. Hamao, T. Inao, Y. Yasuda, C. Morimoto, S.
Okamori, Y. Kaji, T. Yasuda, T. Hajiro, E. Tanaka, Y. Nishimoto, S.
Noma, G. Honjo, Y. Kobashi, Y. Taguchi, Tenri, Japan, p.A6214
207 Differentiating Early Stage and Later Stage IPF Using
Hyperpolarized 129Xe Ventilation MRI/M. He, S.H. Robertson,
J.M. Wang, C.R. Rackley, H.P. McAdams, B. Driehuys, Durham,
NC, p.A6215
208 Longitudinal Change in Lung Function in Patients with
Non-Usual Interstitial Pneumonia Fibrotic Interstitial Lung
Disease/J.S. Sheth, M. Xia, S. Murray, K.R. Flaherty, Ann Arbor,
MI, p.A6216
209 Changes in Body Mass Index as a Prognostic Tool for Patients
with Idiopathic Pulmonary Fibrosis/T. Kulkarni, P. Acosta-Lara,
T. Luckhardt, J.A. De Andrade, D. Kass, K. Gibson, V.J.
Thannickal, S.R. Duncan, Birmingham, AL, p.A6217
210 Morbidity and Mortality of Surgical Lung Biopsy in Interstitial
Lung Disease/T. Lee, M. Brijbassi, T.K. Marras, S. Shapera, J.H.
Fisher, Toronto, Canada, p.A6218
211 MUC5B and Radiologic Subtypes of Interstitial Lung
Abnormalities in the AGES-Reykjavik Study/G. Gudmundsson,
R.K. Putman, T. Araki, E.F. Gudmundsson, M. Nishino, S.
Sigurdsson, G. Eiriksdottir, T. Aspelund, L.J. Launer, T.B. Harris,
I.O. Rosas, D.A. Schwartz, H. Hatabu, V. Gudnason, G.M.
Hunninghake, Reykjavik, Iceland, p.A6219
212 Using a Clinical Data Research Network-Derived Idiopathic
Pulmonary FIbrosis Cohort to Estimate Recruitment Bias in
Clinical Pharmaceutical Trials/A.E.F. Dimmock, R. Bascom, F.
Cordova, K.O. Lindell, K. Gibson, C. Chuang, S.K. Danoff,
Hershey, PA, p.A6220
213 Trajectory of Symptom Burden, Impact and survival in an
Idiopathic Pulmonary Fibrosis Population/A.-M. Russell, M.B.
Scholand, E.A. Snyder, A.-M. Doyle, A.D. Russell, C. Burdett, J.
Lasky, L.A. Saketkoo, London, United Kingdom, p.A6221
ATS 2016 • San Francisco